ADVERTISEMENT

HER2-Targeted Combinations Look Promising

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.  

BY ELIZABETH WHITTINGTON
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
When Herceptin (trastuzumab) was approved in 1998, it signaled the beginning of a drug class that targets a specific growth factor, HER2. On Friday morning at the San Antonio Breast Cancer Symposium, researchers presented a phase 2 study that examined various combinations of the investigational HER2-targeted drug pertuzumab in combination with Herceptin and Taxotere (docetaxel) in patients with early-stage, HER2-positive breast cancer. 

In the NeoSphere (Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation) trial, 417 women were randomized to one of four arms: a combination of pertuzumab and Herceptin with or without Taxotere, Herceptin and Taxotere, or pertuzumab and Taxotere. Upon completion of therapy, all patients underwent surgery and standard treatment of chemotherapy and Herceptin.

Researchers found that 45.8 percent of patients experienced eradication of their tumor when given a combination of pertuzumab, Herceptin and Taxotere, which is statistically significant when compared with the 29 percent found with standard therapy of Herceptin and Taxotere. The pertuzumab and Taxotere group saw a 24 percent eradication of the tumor, also called a pathological complete response.

In patients who received pertuzumab and Herceptin only, 16.8 percent of patients experienced a complete response. This finding led Luca Gianni, MD, director of medical oncology at the National Cancer Institute in Milan, Italy, and lead investigator of the trial, to suggest there might be a subset of patients who would benefit from the combination without chemotherapy. As a next step, researchers are now examining tissue from the study to locate biomarkers that might help identify patients who would benefit from Herceptin and pertuzumab alone, sparing them the side effects of chemotherapy.

Side effects in the trial were not unexpected, and few severe adverse events were seen in the pertuzumab and Herceptin arm. The groups that received Taxotere experienced common side effects associated with the drug, including neutropenia.

In addition, the study design called for neoadjuvant treatment—when drugs are given before surgery to quickly see if they have an effect on the tumor. Traditionally, most drugs are given after surgery to reduce the risk of recurrence, which could occur several years later. Researchers noted that the small trial was remarkable, not only for the results associated with pertuzumab, but also due to the neoadjuvant trial design.

“We strongly believe this neoadjuvant approach allows for rapid testing and ranking of new therapies,” said Gianni during the press conference Friday morning. In addition, researchers are planning a follow-up trial to study the effects of the triple combination given after surgery. 

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Cure Connections
Related Articles
Living With Stage 4 Breast Cancer: My Semi-Charmed Kind of Life
I led a fairly charmed life up until about the age of 29. Life just always seemed to work out for me. I was the gal who had a flat tire 100 yards from the tire shop.
MRI Would Rather Not, Thank You
Male breast cancer survivor discusses a few uncertainties about his first MRI.
Healing in the Key of C: Joy in Music for Cancer Survivors
BY KHEVIN BARNES
The discord of our cancer is only a wrong note in our expression of the score of life. And I believe that, with due diligence and conscious camaraderie with our own bodies, we can live in harmony once more.
It Gets Better After the Shock of an Initial Cancer Diagnosis
A breast cancer and melanoma survivor testifies that her life got better again after hearing she had cancer.
Cancer Should Never Be a Usual Experience
I have a "usually" when it comes to cancer? How could anything ever be usual about cancer? Am I nuts?
Related Videos
Hope Rugo on Managing Sexual Dysfunction From Ovarian Suppression
BY HOPE S. RUGO
Hope S. Rugo discusses managing sexual dysfunction from ovarian suppression treatment for breast cancer.
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
BY HOPE S. RUGO
Hope S. Rugo discusses managing effects from ovarian suppression treatment for breast cancer.
Kara Maxwell Explains Breast Cancer Clinical Trials
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses survivorship for patients with hereditary breast cancer.
$auto_registration$